Global Raynauds Disease Treatment

Raynauds Disease Treatment Comprehensive Study by Type (Primary, Secondary), Application (Hospital, Clinic, Others), Treatment (Medication, - Calcium Channel Blockers, - Vasodilator, Surgeries and Medical Procedures, - Nerve Surgery, - Chemical Injection, Others), Tests (Antinuclear Antibodies Test, Erythrocyte Sedimentation Rate Test, C-reactive Protein Test, Others) Players and Region - Global Market Outlook to 2025

Raynauds Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Raynauds Disease Treatment
Raynauds disease is a common type of health condition that affects the blood flow to certain parts of the body mostly, finger and toes which leads to change in color on the affected area. The disease is triggered by the cold temperatures, stress, and hypertension, the condition occurs temporarily as the blood vessels reach to spasm blocking the blood flow. The color changes from white, then blue and then red as the blood returns to the area. During this time one might experience severe pain, numbness, etc. It can be treated by getting tested, medication, surgeries might also help, most people prefer to avoid it making changes to lifestyle to lead a healthy lifestyle by exercising and taking care of themselves. The primary reasons for getting Raynauds disease are the extremely cold temperature, stress, and hypertension and the chances of this disease might increase because of diseases like lupus, rheumatoid arthritis, and Sjogren's syndrome. The Raynauds disease affects up to 20% of the adult population around the world most common in females than in men, the primary type of this disease usually begins at the age of 20s or 30s and the second type might develop at any age depending on the cause.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Apricus Biosciences Inc. (United States), Harbin Clinic (United States), Pacira (Skyepharma) (United States), Biomag Medical s.r.o. (Czech Republic), Bayer AG (Germany), Healthy Life Pharma Private Limited (India), Duchefa Farma B.V (Netherlands), Pfizer (United States), Teva Pharmaceutical Industries Ltd. (Israel), Apricus Biosciences, Inc. (United States) and Covis Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Human Stem Cells Institute (Russia).

Segmentation Overview
AMA Research has segmented the market of Global Raynauds Disease Treatment market by Type (Primary and Secondary), Application (Hospital, Clinic and Others) and Region.



On the basis of geography, the market of Raynauds Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medication will boost the Raynauds Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tests, the sub-segment i.e. Antinuclear Antibodies Test will boost the Raynauds Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Treatment for Raynauds Disease like Changes in Lifestyle is Growing Due to the Prevailing Causes like Stress and Hypertension and Continuous Research and Development in the Raynauds Disease Treatment

Market Growth Drivers:
Growing Prevalence of Raynauds Phenomenon in People Living in Cold Regions and Increase in the Risk of Raynauds Disease Due to the Disease Lupus, Rheumatoid Arthritis and Sjogren's Syndrome

Challenges:
High-Cost Maintenance and Treatment Equipment Set up Involved in the Raynauds Disease Might Hamper the Market and Lack of Awareness about the Raynauds Disease Might be the Hindrance for the Market

Restraints:
Health Side Effects Associated with Raynauds Disease Treatment to Pregnant Ladies and Regulatory Compliance with Raynauds Disease Treatment

Opportunities:
Various Health Awareness Programs about the Raynaud's Disease Will Drive the Market for Treatments and Rising Severity and Painful Symptoms Associated with Raynaud's Disease is Increasing Demand for Raynauds Disease Treatment


"A number of pharmacologic treatments have been studied, but none provide a cure and none has been approved for this indication in the United States. In an international study of patients with self-reported Raynaud phenomenon, 82% reported that at least one currently used medication was tolerated, but only 16% reported that at least one current medication was effective. For the primary Raynaud phenomenon, the first line of therapy consists of lifestyle measures, such as avoidance of precipitating factors and the use of gloves. If these prove inadequate, the patient may be considered for calcium channel blocker treatment; nifedipine is the usual choice. If lifestyle changes don't control Raynaud's, you may need medicines or surgery. Medicines are used to improve blood flow to the fingers and toes. Examples of medicines used to treat Raynaud's include calcium channel blockers, alpha-blockers, prescription skin creams, and ACE inhibitors (used less often)."

Key Target Audience
Raynauds Disease Treatment Providers, Raynauds Disease Treatment Medication and Equipment Manufacturers, Research and Development Institutes, Potential Investors, Industry Associations, Hospitals and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Primary
  • Secondary
By Application
  • Hospital
  • Clinic
  • Others
By Treatment
  • Medication
  • - Calcium Channel Blockers
  • - Vasodilator
  • Surgeries and Medical Procedures
  • - Nerve Surgery
  • - Chemical Injection
  • Others

By Tests
  • Antinuclear Antibodies Test
  • Erythrocyte Sedimentation Rate Test
  • C-reactive Protein Test
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Raynauds Phenomenon in People Living in Cold Regions
      • 3.2.2. Increase in the Risk of Raynauds Disease Due to the Disease Lupus, Rheumatoid Arthritis and Sjogren's Syndrome
    • 3.3. Market Challenges
      • 3.3.1. High-Cost Maintenance and Treatment Equipment Set up Involved in the Raynauds Disease Might Hamper the Market
      • 3.3.2. Lack of Awareness about the Raynauds Disease Might be the Hindrance for the Market
    • 3.4. Market Trends
      • 3.4.1. Treatment for Raynauds Disease like Changes in Lifestyle is Growing Due to the Prevailing Causes like Stress and Hypertension
      • 3.4.2. Continuous Research and Development in the Raynauds Disease Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Raynauds Disease Treatment, by Type, Application, Treatment, Tests and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Raynauds Disease Treatment (Value)
      • 5.2.1. Global Raynauds Disease Treatment by: Type (Value)
        • 5.2.1.1. Primary
        • 5.2.1.2. Secondary
      • 5.2.2. Global Raynauds Disease Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Raynauds Disease Treatment by: Treatment (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. - Calcium Channel Blockers
        • 5.2.3.3. - Vasodilator
        • 5.2.3.4. Surgeries and Medical Procedures
        • 5.2.3.5. - Nerve Surgery
        • 5.2.3.6. - Chemical Injection
        • 5.2.3.7. Others
      • 5.2.4. Global Raynauds Disease Treatment by: Tests (Value)
        • 5.2.4.1. Antinuclear Antibodies Test
        • 5.2.4.2. Erythrocyte Sedimentation Rate Test
        • 5.2.4.3. C-reactive Protein Test
        • 5.2.4.4. Others
      • 5.2.5. Global Raynauds Disease Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Raynauds Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Apricus Biosciences Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Harbin Clinic (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pacira (Skyepharma) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biomag Medical s.r.o. (Czech Republic)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Healthy Life Pharma Private Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Duchefa Farma B.V (Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Apricus Biosciences, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Covis Pharmaceuticals, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Raynauds Disease Treatment Sale, by Type, Application, Treatment, Tests and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Raynauds Disease Treatment (Value)
      • 7.2.1. Global Raynauds Disease Treatment by: Type (Value)
        • 7.2.1.1. Primary
        • 7.2.1.2. Secondary
      • 7.2.2. Global Raynauds Disease Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Raynauds Disease Treatment by: Treatment (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. - Calcium Channel Blockers
        • 7.2.3.3. - Vasodilator
        • 7.2.3.4. Surgeries and Medical Procedures
        • 7.2.3.5. - Nerve Surgery
        • 7.2.3.6. - Chemical Injection
        • 7.2.3.7. Others
      • 7.2.4. Global Raynauds Disease Treatment by: Tests (Value)
        • 7.2.4.1. Antinuclear Antibodies Test
        • 7.2.4.2. Erythrocyte Sedimentation Rate Test
        • 7.2.4.3. C-reactive Protein Test
        • 7.2.4.4. Others
      • 7.2.5. Global Raynauds Disease Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Raynauds Disease Treatment: by Type(USD Million)
  • Table 2. Raynauds Disease Treatment Primary , by Region USD Million (2016-2021)
  • Table 3. Raynauds Disease Treatment Secondary , by Region USD Million (2016-2021)
  • Table 4. Raynauds Disease Treatment: by Application(USD Million)
  • Table 5. Raynauds Disease Treatment Hospital , by Region USD Million (2016-2021)
  • Table 6. Raynauds Disease Treatment Clinic , by Region USD Million (2016-2021)
  • Table 7. Raynauds Disease Treatment Others , by Region USD Million (2016-2021)
  • Table 8. Raynauds Disease Treatment: by Treatment(USD Million)
  • Table 9. Raynauds Disease Treatment Medication , by Region USD Million (2016-2021)
  • Table 10. Raynauds Disease Treatment - Calcium Channel Blockers , by Region USD Million (2016-2021)
  • Table 11. Raynauds Disease Treatment - Vasodilator , by Region USD Million (2016-2021)
  • Table 12. Raynauds Disease Treatment Surgeries and Medical Procedures , by Region USD Million (2016-2021)
  • Table 13. Raynauds Disease Treatment - Nerve Surgery , by Region USD Million (2016-2021)
  • Table 14. Raynauds Disease Treatment - Chemical Injection , by Region USD Million (2016-2021)
  • Table 15. Raynauds Disease Treatment Others , by Region USD Million (2016-2021)
  • Table 16. Raynauds Disease Treatment: by Tests(USD Million)
  • Table 17. Raynauds Disease Treatment Antinuclear Antibodies Test , by Region USD Million (2016-2021)
  • Table 18. Raynauds Disease Treatment Erythrocyte Sedimentation Rate Test , by Region USD Million (2016-2021)
  • Table 19. Raynauds Disease Treatment C-reactive Protein Test , by Region USD Million (2016-2021)
  • Table 20. Raynauds Disease Treatment Others , by Region USD Million (2016-2021)
  • Table 21. South America Raynauds Disease Treatment, by Country USD Million (2016-2021)
  • Table 22. South America Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 23. South America Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 24. South America Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 25. South America Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 26. Brazil Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 27. Brazil Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 28. Brazil Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 29. Brazil Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 30. Argentina Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 31. Argentina Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 32. Argentina Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 33. Argentina Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 34. Rest of South America Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 35. Rest of South America Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 36. Rest of South America Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 37. Rest of South America Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 38. Asia Pacific Raynauds Disease Treatment, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 40. Asia Pacific Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 41. Asia Pacific Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 42. Asia Pacific Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 43. China Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 44. China Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 45. China Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 46. China Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 47. Japan Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 48. Japan Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 49. Japan Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 50. Japan Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 51. India Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 52. India Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 53. India Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 54. India Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 55. South Korea Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 56. South Korea Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 57. South Korea Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 58. South Korea Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 59. Taiwan Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 60. Taiwan Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 61. Taiwan Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 62. Taiwan Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 63. Australia Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 64. Australia Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 65. Australia Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 66. Australia Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 71. Europe Raynauds Disease Treatment, by Country USD Million (2016-2021)
  • Table 72. Europe Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 73. Europe Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 74. Europe Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 75. Europe Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 76. Germany Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 77. Germany Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 78. Germany Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 79. Germany Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 80. France Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 81. France Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 82. France Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 83. France Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 84. Italy Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 85. Italy Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 86. Italy Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 87. Italy Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 88. United Kingdom Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 89. United Kingdom Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 90. United Kingdom Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 91. United Kingdom Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 92. Netherlands Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 93. Netherlands Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 94. Netherlands Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 95. Netherlands Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 96. Rest of Europe Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 97. Rest of Europe Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 98. Rest of Europe Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 99. Rest of Europe Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 100. MEA Raynauds Disease Treatment, by Country USD Million (2016-2021)
  • Table 101. MEA Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 102. MEA Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 103. MEA Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 104. MEA Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 105. Middle East Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 106. Middle East Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 107. Middle East Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 108. Middle East Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 109. Africa Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 110. Africa Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 111. Africa Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 112. Africa Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 113. North America Raynauds Disease Treatment, by Country USD Million (2016-2021)
  • Table 114. North America Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 115. North America Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 116. North America Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 117. North America Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 118. United States Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 119. United States Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 120. United States Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 121. United States Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 122. Canada Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 123. Canada Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 124. Canada Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 125. Canada Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 126. Mexico Raynauds Disease Treatment, by Type USD Million (2016-2021)
  • Table 127. Mexico Raynauds Disease Treatment, by Application USD Million (2016-2021)
  • Table 128. Mexico Raynauds Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 129. Mexico Raynauds Disease Treatment, by Tests USD Million (2016-2021)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Raynauds Disease Treatment: by Type(USD Million)
  • Table 142. Raynauds Disease Treatment Primary , by Region USD Million (2022-2027)
  • Table 143. Raynauds Disease Treatment Secondary , by Region USD Million (2022-2027)
  • Table 144. Raynauds Disease Treatment: by Application(USD Million)
  • Table 145. Raynauds Disease Treatment Hospital , by Region USD Million (2022-2027)
  • Table 146. Raynauds Disease Treatment Clinic , by Region USD Million (2022-2027)
  • Table 147. Raynauds Disease Treatment Others , by Region USD Million (2022-2027)
  • Table 148. Raynauds Disease Treatment: by Treatment(USD Million)
  • Table 149. Raynauds Disease Treatment Medication , by Region USD Million (2022-2027)
  • Table 150. Raynauds Disease Treatment - Calcium Channel Blockers , by Region USD Million (2022-2027)
  • Table 151. Raynauds Disease Treatment - Vasodilator , by Region USD Million (2022-2027)
  • Table 152. Raynauds Disease Treatment Surgeries and Medical Procedures , by Region USD Million (2022-2027)
  • Table 153. Raynauds Disease Treatment - Nerve Surgery , by Region USD Million (2022-2027)
  • Table 154. Raynauds Disease Treatment - Chemical Injection , by Region USD Million (2022-2027)
  • Table 155. Raynauds Disease Treatment Others , by Region USD Million (2022-2027)
  • Table 156. Raynauds Disease Treatment: by Tests(USD Million)
  • Table 157. Raynauds Disease Treatment Antinuclear Antibodies Test , by Region USD Million (2022-2027)
  • Table 158. Raynauds Disease Treatment Erythrocyte Sedimentation Rate Test , by Region USD Million (2022-2027)
  • Table 159. Raynauds Disease Treatment C-reactive Protein Test , by Region USD Million (2022-2027)
  • Table 160. Raynauds Disease Treatment Others , by Region USD Million (2022-2027)
  • Table 161. South America Raynauds Disease Treatment, by Country USD Million (2022-2027)
  • Table 162. South America Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 163. South America Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 164. South America Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 165. South America Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 166. Brazil Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 167. Brazil Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 168. Brazil Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 169. Brazil Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 170. Argentina Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 171. Argentina Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 172. Argentina Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 173. Argentina Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 174. Rest of South America Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 175. Rest of South America Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 176. Rest of South America Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 177. Rest of South America Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 178. Asia Pacific Raynauds Disease Treatment, by Country USD Million (2022-2027)
  • Table 179. Asia Pacific Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 180. Asia Pacific Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 181. Asia Pacific Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 182. Asia Pacific Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 183. China Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 184. China Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 185. China Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 186. China Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 187. Japan Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 188. Japan Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 189. Japan Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 190. Japan Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 191. India Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 192. India Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 193. India Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 194. India Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 195. South Korea Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 196. South Korea Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 197. South Korea Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 198. South Korea Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 199. Taiwan Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 200. Taiwan Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 201. Taiwan Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 202. Taiwan Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 203. Australia Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 204. Australia Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 205. Australia Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 206. Australia Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 210. Rest of Asia-Pacific Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 211. Europe Raynauds Disease Treatment, by Country USD Million (2022-2027)
  • Table 212. Europe Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 213. Europe Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 214. Europe Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 215. Europe Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 216. Germany Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 217. Germany Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 218. Germany Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 219. Germany Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 220. France Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 221. France Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 222. France Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 223. France Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 224. Italy Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 225. Italy Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 226. Italy Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 227. Italy Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 228. United Kingdom Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 229. United Kingdom Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 230. United Kingdom Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 231. United Kingdom Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 232. Netherlands Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 233. Netherlands Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 234. Netherlands Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 235. Netherlands Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 236. Rest of Europe Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 237. Rest of Europe Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 238. Rest of Europe Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 239. Rest of Europe Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 240. MEA Raynauds Disease Treatment, by Country USD Million (2022-2027)
  • Table 241. MEA Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 242. MEA Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 243. MEA Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 244. MEA Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 245. Middle East Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 246. Middle East Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 247. Middle East Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 248. Middle East Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 249. Africa Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 250. Africa Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 251. Africa Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 252. Africa Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 253. North America Raynauds Disease Treatment, by Country USD Million (2022-2027)
  • Table 254. North America Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 255. North America Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 256. North America Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 257. North America Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 258. United States Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 259. United States Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 260. United States Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 261. United States Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 262. Canada Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 263. Canada Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 264. Canada Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 265. Canada Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 266. Mexico Raynauds Disease Treatment, by Type USD Million (2022-2027)
  • Table 267. Mexico Raynauds Disease Treatment, by Application USD Million (2022-2027)
  • Table 268. Mexico Raynauds Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 269. Mexico Raynauds Disease Treatment, by Tests USD Million (2022-2027)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Raynauds Disease Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Raynauds Disease Treatment: by Application USD Million (2016-2021)
  • Figure 6. Global Raynauds Disease Treatment: by Treatment USD Million (2016-2021)
  • Figure 7. Global Raynauds Disease Treatment: by Tests USD Million (2016-2021)
  • Figure 8. South America Raynauds Disease Treatment Share (%), by Country
  • Figure 9. Asia Pacific Raynauds Disease Treatment Share (%), by Country
  • Figure 10. Europe Raynauds Disease Treatment Share (%), by Country
  • Figure 11. MEA Raynauds Disease Treatment Share (%), by Country
  • Figure 12. North America Raynauds Disease Treatment Share (%), by Country
  • Figure 13. Global Raynauds Disease Treatment share by Players 2021 (%)
  • Figure 14. Global Raynauds Disease Treatment share by Players (Top 3) 2021(%)
  • Figure 15. Global Raynauds Disease Treatment share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Apricus Biosciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Apricus Biosciences Inc. (United States) Revenue: by Geography 2021
  • Figure 19. Harbin Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 20. Harbin Clinic (United States) Revenue: by Geography 2021
  • Figure 21. Pacira (Skyepharma) (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pacira (Skyepharma) (United States) Revenue: by Geography 2021
  • Figure 23. Biomag Medical s.r.o. (Czech Republic) Revenue, Net Income and Gross profit
  • Figure 24. Biomag Medical s.r.o. (Czech Republic) Revenue: by Geography 2021
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 27. Healthy Life Pharma Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 28. Healthy Life Pharma Private Limited (India) Revenue: by Geography 2021
  • Figure 29. Duchefa Farma B.V (Netherlands) Revenue, Net Income and Gross profit
  • Figure 30. Duchefa Farma B.V (Netherlands) Revenue: by Geography 2021
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2021
  • Figure 33. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 35. Apricus Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Apricus Biosciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Covis Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Covis Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 39. Global Raynauds Disease Treatment: by Type USD Million (2022-2027)
  • Figure 40. Global Raynauds Disease Treatment: by Application USD Million (2022-2027)
  • Figure 41. Global Raynauds Disease Treatment: by Treatment USD Million (2022-2027)
  • Figure 42. Global Raynauds Disease Treatment: by Tests USD Million (2022-2027)
  • Figure 43. South America Raynauds Disease Treatment Share (%), by Country
  • Figure 44. Asia Pacific Raynauds Disease Treatment Share (%), by Country
  • Figure 45. Europe Raynauds Disease Treatment Share (%), by Country
  • Figure 46. MEA Raynauds Disease Treatment Share (%), by Country
  • Figure 47. North America Raynauds Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Apricus Biosciences Inc. (United States)
  • Harbin Clinic (United States)
  • Pacira (Skyepharma) (United States)
  • Biomag Medical s.r.o. (Czech Republic)
  • Bayer AG (Germany)
  • Healthy Life Pharma Private Limited (India)
  • Duchefa Farma B.V (Netherlands)
  • Pfizer (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Apricus Biosciences, Inc. (United States)
  • Covis Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Human Stem Cells Institute (Russia)
Select User Access Type

Key Highlights of Report


Feb 2020 233 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Raynauds Disease Treatment Quantitative research analysis
Global Raynauds Disease Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Apricus Biosciences Inc. (United States), Harbin Clinic (United States), Pacira (Skyepharma) (United States), Biomag Medical s.r.o. (Czech Republic), Bayer AG (Germany), Healthy Life Pharma Private Limited (India), Duchefa Farma B.V (Netherlands), Pfizer (United States), Teva Pharmaceutical Industries Ltd. (Israel), Apricus Biosciences, Inc. (United States) and Covis Pharmaceuticals, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Treatment for Raynauds Disease like Changes in Lifestyle is Growing Due to the Prevailing Causes like Stress and Hypertension " is seen as one of major influencing trends for Raynauds Disease Treatment Market during projected period 2021-2027.
The Raynauds Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Raynauds Disease Treatment Report?

Have a Query? Click Here

Other Related Reports

Plasma Therapy Comprehensive Study by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), Application (Orthopedics (Arthritis, Chronic Tendinitis, Bon...
$ 3750
Poultry Bacteriology Diagnostics Comprehensive Study by Type (ELISA Test, PCR Test, Others), Application (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Mycoplasmosis, Avian Pasteurel...
$ 3750
Cold Pain Therapy Comprehensive Study by Type (OTC-Based Products, Prescription-Based Products), Application (Musculoskeletal Disorders, Sport Medicine, Physical Therapy, Post Operative Therapy, Post...
$ 3450
Synovial Sarcoma Treatment Comprehensive Study by Type (High-grade, Low-grade, Translocation-associated), End Users (Hospitals, Specialty Clinics, Oncology Centers, Other), Treatment (Surgery, Anti-A...
$ 3500
Hairy Cell Leukemia Therapeutics Comprehensive Study by Type (Chemotherapy {Cladribine, Pentostatin}, Biologic Therapy {Rituximab, Interferon}, Splenectomy), Application (Hospital, Clinic, Others), D...
$ 3750
Medulloblastoma Drug Comprehensive Study by Type (Dianhydrogalactitol, IMP-5471, Ipilimumab, Indoximod, Others), Application (Hospital, Clinic, Others), Treatment (Surgery, Radiation Therapy, Chemoth...
$ 3350